The International Suicide Prevention Trial (InterSePT): Rationale and design of a trial comparing the relative ability of clozapine and olanzapine to reduce suicidal behavior in schizophrenia and schizoaffective patients

Schizophrenia Bulletin

Volumn 30, Issue 3, 2004, Pages 577-586

  Alphs, Larry ^a,b   Anand, Ravi ^a   Islam, M Zahur ^c   Meltzer, Herbert Y ^d   Kane, John M ^e   Krishnan, Ranga ^f   Green, Alan I ^g   Potkin, Steven ^h   Chouinard, Guy ⁱ   Lindenmayer, Jean Pierre ^j   Kerwin, Rob ^k  

^a Pfizer Global Res and Development ^*

^b PFIZER INC   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

^d VANDERBILT UNIVERSITY   (United States)

^e LONG ISLAND JEWISH MEDICAL CENTER   (United States)

^f DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g DARTMOUTH COLLEGE   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ MCGILL UNIVERSITY   (Canada)

^j MANHATTAN PSYCHIATRIC CENTER   (United States)

^k KING'S COLLEGE LONDON   (United Kingdom)

more..

Author keywords

Clozapine; Olanzapine; Schizoaffective disorder; Schizophrenia; Study design; Suicidal behavior; Suicide

Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE;

ADULT; AKATHISIA; ANXIETY; CLINICAL TRIAL; DEPRESSION; DRUG EFFICACY; EXTRAPYRAMIDAL SYMPTOM; HUMAN; MAJOR CLINICAL STUDY; MENTAL DISEASE; OPEN STUDY; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RATING SCALE; REVIEW; RISK FACTOR; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SINGLE BLIND PROCEDURE; SUICIDAL BEHAVIOR; SUICIDE; TARDIVE DYSKINESIA; TREATMENT OUTCOME;

EID: 10344225140     PISSN: 05867614     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.schbul.a007102     Document Type: Review

References (36)

1. Addington, D.; Addington, J.; and Maticka-Tindale, E. Specificity of the Calgary Depression Scale for schizophrenics. Schizophrenia Research, 11:239-244, 1994.
2. American Psychiatric Association. DSM-IV: Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: APA, 1994.
3. Axelsson, R., and Lagerkvist-Briggs, M. Factors predicting suicide in psychotic patients. European Archives of Psychiatry and Clinical Neuroscience, 241:259-266, 1992.
4. Beck, A.T.; Kovacs, M.; and Weissman, A. Assessment of suicidal intention: The Scale for Suicide Ideation. Journal of Consulting and Clinical Psychology, 2:343-352, 1979.
5. Beisser, A.R., and Blanchette, J.E. A study of suicides in a mental hospital. Diseases of the Nervous System, 22:365-369, 1961.
6. Bleuler, F. Dementia Praecox or the Group of Schizophrenias. (1911) Translated by J. Zinkin. New York, NY: International Universities Press, 1950.
7. Chouinard, G.; Ross-Chouinard, A.; Annable, L.; and Jones, B.D. Extrapyramidal symptom rating scale. Canadian Journal of Neurological Science, 7(3):233, 1980.
8. Cohen, L.J.; Test, M.A.; and Brown, R.L. Suicide and schizophrenia: Data from a prospective community treatment study. American Journal of Psychiatry, 147:602-607, 1990.
9. Cohen, S.; Leonard, C.V.; Farberow, N.L.; Schneidman, E.S. Tranquilizers and suicide in the schizophrenic patient. Archives of General Psychiatry, 11:312-321, 1964.
10. Covi, L.; Rickels, K.; and Lipman, O.S. Effects of psychotropic agents on depression. Psychopharmacology Bulletin, 100-101, 1981.
11. Freedman, L.S. Tables of the number of patients required in clinical trials using the log rank test. Statistics in Medicine, 1:121-129, 1982.
12. Hussar, A.E. Effect of tranquilizers on medical morbidity and mortality in a mental hospital. Journal of the American Medical Association, 179:682-686, 1962.
13. Johnson, D.A.; Pasterski, G.; Ludlow, J.M.; Street, K.; and Taylor, R.D. The discontinuance of maintenance neuroleptic therapy in chronic schizophrenic patients: Drug and social consequences. Acta Psychiatrica Scandinavica, 67:339-352, 1983.
14. Khan, A.; Khan, S.R.; Leventhal, R.M.; and Brown, W.A. Symptom reduction and suicide risk among patients treated with placebo in antipsychotic clinical trials: An analysis of the Food and Drug Administration data base. American Journal of Psychiatry, 158:1449-1454, 2001.
15. Kline, N.S. Psychopharmaceuticals: Effects and side-effects. Bulletin of the WHO, 21:397-410, 1959.
16. Lindenmayer, J.P.; Bernstein-Hyman, R.; and Grochowski, S. A new five-factor model of schizophrenia. Psychiatric Quarterly, 65:299-322, 1994.
17. Lindenmayer, J.P.; Czobor, P.; Alphs, L.D.; Nathan, A.M.; Anand, R.; Islam, Z.; Chou, J.C.; and the InterSePT Study Group. The InterSePT scale for suicidal thinking: Reliability and validity. Schizophrenia Research, 63:161-170, 2003.
18. Margolese, H.C.; Chouinard, G.; Larach, V.W.; and Beauclair, L. Relationship between antipsychotic-induced akathisia and tardive dyskinesia and suicidality in schizophrenia: Impact of clozapine and olanzapine. Acta Psychiatrica Belgica, 101:128-144, 2001.
19. Meltzer, H.Y. Suicide and schizophrenia: Clozapine and the InterSePT study. International Clozaril/Leponex Suicide Prevention Trial. Journal of Clinical Psychiatry, 60(Suppl, 12):47-50, 1999.
20. Meltzer, H.Y., and Fatemi, H. Suicide in schizophrenia: The effect of clozapine. Clinical Neuropharmacology, 18:S18-S24, 1995.
21. Meltzer, H.Y., and Okayli, G. Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: Impact on risk-benefit assessment. American Journal of Psychiatry, 152(2): 183-190, 1995.
22. Meltzer, H.Y.; Alphs, L.; Altamura, C.; Anand, R.; Bertoldi, A.; Bourgeois, M.; Green, A.I.; Islam, M.Z.; Kane, J.; Krishnan, R.; Lindenmayer, J.-P.; and Potkin, S. Reduced suicidality in schizophrenia and schizoaffective disorder with clozapine: Report of the International Suicide Prevention Trial (InterSePT). Archives of General Psychiatry, 60:82-91, 2003. Erratum in Archives of General Psychiatry, 60(7):735, 2003.
23. Meltzer, H.Y.; Alphs, L.; Altamura, C.; Anand, R.; Bertoldi, A.; Bourgeois, M.; Green, A.I.; Islam, M.Z.; Kane, J.; Krishnan, R.; Lindenmayer, J.-P.; and Potkin, S. Reduced suicidality in schizophrenia and schizoaffective disorder with clozapine: Report of the International Suicide Prevention Trial (InterSePT). Archives of General Psychiatry, 60:82-91, 2003. Erratum in Archives of General Psychiatry, 60(7):735, 2003.
24. Munro, J.; O'Sullivan, D.; Andrews, C.; Arana, A.; Mortimer, A.; and Kerwin, R. Active monitoring of 12,760 clozapine recipients in the U.K. and Ireland. British Journal of Psychiatry, 175:576-580, 1999.
25. Nyman, A., and Jonsson, H. Patterns of self-destructive behavior in schizophrenia. Acta Psychiatrica Scandinavica, 73:252-262, 1986.
26. Palmer, D.D.; Hunter, I.D.; and Wyatt, R.J. Do antipsychotic medications decrease the risk of suicide in patients with schizophrenia? Journal of Clinical Psychiatry, 60(Suppl. 2):100-103, 1999.
27. Planansky, K., and Johnston, R. The occurrence and characteristics of suicidal preoccupation and acts in schizophrenia. Acta Psychiatrica Scandinavica, 47:473-483, 1971.
28. Reid, W.H.; Mason, M.; and Hogan, T. Suicide prevention effects associated with clozapine therapy in schizophrenia and schizoaffective disorder. Psychiatric Services, 49:1029-1033, 1998.
29. Rennie, T. Follow-up study of five hundred patients with schizophrenia to 1923. Archives of Neurology and Psychiatry, 41:877-891, 1939.
30. Sernyak, M.J.; Desia, R.; Stolar, M.; and Rosenheck, R. Impact of clozapine on completed suicide. American Journal of Psychiatry, 158:931-937, 2001.
31. Singh, B.S. Suicide: The public health crisis of our time. Australian and New Zealand Journal of Medicine, 28:295-300, 1998.
32. Stephens, J.H.; Richard, P.; and McHugh, P.R. Suicide in patients hospitalized for schizophrenia: 1913-1940. Journal of Nervous and Mental Disease, 187:10-14, 1999.
33. Tran, P.V.; Hamilton, S.H.; Kuntz, A.J.; Potvin, J.H.; Andersen, S.W.; Beasley, C., Jr.; and Tollefson, G.D. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. Journal of Clinical Psychopharmacology, 17:407-418, 1997.
34. Walker, A.M.; Lanza, L.L.; Arellano, F.; and Rothman, K.J. Mortality in current and former users of clozapine. Epidemiology, 8:671-677, 1997.
35. Wei, L.J.; Lin, D.Y.; and Weissfeld, L. Regression analysis of multivariate incomplete failure time data by modeling marginal distributions. Journal of the American Statistical Association, 84:1065-1073, 1989.
36. Winokur, G., and Tsuang, M. The Iowa 500: Suicide in mania, depression, and schizophrenia. American Journal of Psychiatry, 6:650-651, 1975.